The Challenge of Severe Pediatric Epilepsy
Epilepsy affects approximately 470,000 children in the United States, according to the Centers for Disease Control and Prevention. While many achieve seizure control through standard antiepileptic drugs (AEDs), a significant number suffer from severe forms that do not respond to conventional treatment. These include rare genetic conditions like Dravet Syndrome and Lennox-Gastaut Syndrome, both of which are characterized by frequent, intense seizures that can lead to developmental delays, cognitive impairment, and reduced quality of life.
For parents of children with these conditions, each day can bring unpredictable and dangerous medical emergencies. Many children endure multiple seizures daily, with some experiencing hundreds per week. Standard treatments often come with side effects—ranging from drowsiness and irritability to liver damage—further complicating care and limiting quality of life.
Cannabidiol: A Game-Changer in Epilepsy Treatment
The turning point in cannabis-based epilepsy treatment came with increasing scientific interest in cannabidiol (CBD), a non-intoxicating cannabinoid found in the marijuana plant. Unlike THC, the psychoactive compound commonly associated with cannabis, CBD does not produce a “high.” Instead, it interacts with the body’s endocannabinoid system in ways that appear to regulate neuronal excitability and reduce seizure activity.
Pioneering studies conducted over the past decade have underscored CBD’s effectiveness. A landmark 2017 clinical trial published in the New England Journal of Medicine demonstrated that CBD significantly reduced seizure frequency in children with Dravet Syndrome. In the study, children treated with cannabidiol saw a median reduction in convulsive seizures of 39%, compared to just 13% in the placebo group.
In 2018, these findings contributed to the FDA’s approval of Epidiolex, a purified form of CBD extracted from cannabis, for the treatment of both Dravet Syndrome and Lennox-Gastaut Syndrome. This marked a historic milestone: Epidiolex became the first cannabis-derived pharmaceutical approved for use in the United States.
Another randomized clinical trial, published in The Lancet Neurology, examined Epidiolex’s effects on Lennox-Gastaut Syndrome and found similarly compelling results. Patients taking CBD experienced a drop seizure reduction of 44%, while the placebo group saw a reduction of just 22%. These reductions, while not curative, often translate into substantial improvements in daily functioning and safety.
Real-World Impact: Families and Lives Changed
Behind the clinical data are countless personal stories of transformation. Some parents report that CBD has reduced their child’s seizure frequency from dozens per day to just a few per week—or even none at all. For these families, CBD has restored not only health but also hope.
Moreover, improvements often go beyond seizure control. Caregivers frequently observe gains in sleep quality, social interaction, attention span, and overall mood. While medical marijuana is not without side effects—such as fatigue, decreased appetite, or liver enzyme elevation—it is often better tolerated than many conventional AEDs.
The Path Forward
Though medical marijuana is now legal in many U.S. states and approved for pediatric epilepsy in the form of Epidiolex, access and acceptance still vary widely. Insurance coverage can be inconsistent, and federal regulations continue to restrict broader research and development.
Nonetheless, the success of CBD-based treatment has spurred a new wave of research into cannabinoid therapies for other neurological disorders. Scientists continue to investigate optimal dosing strategies, long-term effects, and the potential role of other cannabis compounds such as cannabidivarin (CBDV) and tetrahydrocannabivarin (THCV).
In a field long dominated by limited and often ineffective pharmaceutical options, medical marijuana has opened the door to a new era in epilepsy care—one driven by science, shaped by advocacy, and sustained by families who refuse to give up.
References
Devinsky, O., et al. (2017). Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. New England Journal of Medicine.
U.S. Food and Drug Administration. (2018). FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy.
Thiele, E.A., et al. (2018). Cannabidiol in patients with Lennox–Gastaut syndrome: a randomized, double-blind, placebo-controlled trial. The Lancet Neurology.
Dabbin-Dad Newsroom
If you liked this post, say thanks by sharing it
